Red Tree Venture Capital

Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets.

Engrail Therapeutics, Inc. is dedicated to developing and commercializing neuro drugs aimed at treating diseases of the nervous system. Founded in 2019 and based in San Diego, California, the company focuses on creating transformative medicines to alleviate the significant burden of such conditions. One of its key products is ENX-101, a preclinical compound designed to modulate a receptor for GABA, a critical neurotransmitter in the brain. Engrail Therapeutics combines biological insights with clinically meaningful solutions to advance its portfolio of therapies, utilizing a flexible transaction model to efficiently progress its drug candidates from development to commercialization.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

Tachyon Therapeutics is a biotechnology company focused on developing innovative therapeutics for cancer treatment. The firm specializes in creating selective compounds that target significant drug targets within cancer biology, employing advanced methodologies in molecular cancer biology, epigenetics, and cancer stem cell biology. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead compound, TACH101, in patients with advanced cancer. The company's research and development efforts aim to unlock new pathways for treating challenging cancer types, ensuring that its programs are advanced in a timely and scientifically rigorous manner.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Rondo Therapeutics is a biotechnology company focused on the discovery and development of novel bispecific antibodies aimed at activating the immune system to combat cancer. Founded in 2021 and based in Hayward, California, the company specializes in creating cancer immunotherapies specifically for solid tumor types that do not respond to conventional immune checkpoint inhibitors. By targeting areas of unmet medical need, Rondo Therapeutics enables researchers to advance innovative drug solutions in the fight against cancer.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

Magnus Medical focuses on developing a closed-loop neuromodulation technology aimed at treating intractable neurological and psychiatric disorders. This innovative brain stimulation method has shown the potential for rapid and significant results by producing identifiable changes in brain networks. The technology enables individuals to manage their symptoms effectively and aims to restore and sustain mental health, offering a new approach for those struggling with persistent mental health challenges.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Ceribell, Inc. is a medical technology company that designs and manufactures devices for electroencephalography (EEG) data acquisition and interpretation, aimed at improving the diagnosis and management of neurological conditions. Its flagship product, the Ceribell EEG System, includes a flexible EEG Headband that accommodates various hair types and head sizes, alongside a portable EEG Recorder that ensures clinical-quality data and on-device display. The system is designed to be set up by any healthcare provider within six minutes, making EEG testing more accessible and efficient. Notably, it features a unique function that converts brainwaves into sound, allowing for quicker detection of seizures without the need for specialized technicians. This innovation facilitates earlier diagnosis and targeted treatment for patients, particularly for non-convulsive seizures, thereby reducing the risk of complications and improving overall patient outcomes. Established in 2014 and based in Mountain View, California, Ceribell is committed to enhancing care in hospital ICUs, inpatient units, and emergency departments.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.